Evaluating Novel Anticoagulant and Antiplatelet Drugs for Thromboembolic Illness Prevention and Treatment

DOACs anticoagulant antiplatelet thromboembolic diseases stroke prevention venous thromboembolism atrial fibrillation

Authors

May 25, 2024

Downloads

Infarction of the deep veins (DVT) and pulmonary embolism, and stroke are examples of thromboembolic illnesses that are principal causes of mortality and morbidity on a global scale. The development of novel anticoagulant and antiplatelet medications has fundamentally changed the prevention and treatment of these illnesses. This article evaluates the safety and efficacy of these cutting-edge therapeutic treatments, with a focus on direct oral anticoagulants (DOACs) and new antiplatelet drugs. An examination of recent clinical trials and real-world data provides a comprehensive assessment of their benefits and drawbacks.

Similar Articles

1 2 3 4 5 6 7 8 9 10 > >> 

You may also start an advanced similarity search for this article.